Singapore, Jan. 23 -- South Korea-based SK bioscience has announced that it is advancing the development of a Zaire ebolavirus vaccine under a new collaboration supported by Norway's Coalition for Epidemic Preparedness Innovations (CEPI).

The announcement follows a funding agreement between CEPI and global pharmaceutical company MSD to support continued development of a Zaire ebolavirus vaccine. Under the agreement, CEPI will provide up to $30 million in funding to MSD, which will allocate the funding to its development partners, including SK bioscience and Hilleman Laboratories-a joint venture between MSD and Wellcome, a global charitable foundation focused on health research-to carry out key research, manufacturing process improvement ...